infigratinib,pembrolizumab
bridgebio pharmaceutical,merck
['infigratinib', 'bladder', 'mibc', 'proof 302', ' uc,(-ucsd),(-ucsf),', 'pembro']
dr. de santis highlights ph ii gem+pembro+rt bladder sparing tx muscle-invasive uc 2-yr update w/71% bladder intact dfs, 83% 2-yr os rate &amp; adj infigratinib w/fgfr3+ utuc/mibc w/prev 19% for fgfr3 alts of 617 tissues screened from ph iii proof 302 study #asco23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope